Taking CoQ10 to Lower Blood Pressure
double coronary bypass :: Article Creator University Of Calgary Joins The Phase II Trial Of LSALT Peptide Targeting Cardiac Surgery Associated-Acute Kidney Injury TORONTO, March 15, 2024 (GLOBE NEWSWIRE) -- Arch Biopartners Inc., ("Arch" or the "Company") (TSX Venture: ARCH and OTCQB: ACHFF), announced today that a research team from the University of Calgary's Cumming School of Medicine has joined the Phase II trial for LSALT peptide targeting the prevention and treatment of cardiac surgery-associated acute kidney injury (CS-AKI). LSALT peptide is the Company's lead drug candidate for preventing and treating inflammation injury in the kidneys, lungs and liver. "We know that acute kidney injury impairs recovery and can negatively affect long-term outcomes following heart surgery. Our research team is excited to participate in a study working towards improving kidney health in our patients." said Alex Gregory M...